COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
- for people ages 18 years and up (full criteria)
- at UCLA
- study startedestimated completion
Advanced Cancer Ovarian Cancer Breast Cancer Lung Cancer Endometrial Cancer Ovarian Neoplasm Triple Negative Breast Cancer Lung Neoplasm Neoplasm Malignant Colo-rectal Cancer PVRIG checkpoint inhibitor DNAM (DNAX Accessory molecule 1) PD-1 inhibitor CD112 CD 112R Poliovirus receptor-related immunoglobulin PVRL2 Nivolumab opdivo TIGIT antibody COM902 Breast Neoplasms Neoplasms Ovarian Neoplasms Endometrial Neoplasms Triple Negative Breast Neoplasms Lung Neoplasms COM701 COM701 with Opdivo (Nivolumab).
- accepting new patients
- Start Date
- Completion Date
- Compugen Ltd
- Phase 1 Research Study
- Study Type
- Expecting 140 study participants
- Last Updated